Evidence map›Paper›PMID 35773644›Full record

ArticleBMC gastroenterology2022

Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis.

Kushala W M Abeysekera, James G Orr, Fiona H Gordon, Laura D Howe, Julian Hamilton-Shield, Jon Heron, Matthew Hickman

Open access · goldAbstract read
In one paragraph

Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kushala W M AbeysekeraPopulation Health Science, Bristol Medical School, University of Bristol, Bristol, UK. k.abeysekera@bristol.ac.uk.
James G OrrDepartment of Liver Medicine, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Fiona H GordonDepartment of Liver Medicine, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Laura D HowePopulation Health Science, Bristol Medical School, University of Bristol, Bristol, UK.
Julian Hamilton-ShieldNIHR Bristol Biomedical Research Centre, Nutrition Theme, University Hospitals Bristol and Weston NHS Foundation Trust & University of Bristol, Bristol, UK.
Jon HeronPopulation Health Science, Bristol Medical School, University of Bristol, Bristol, UK.
Matthew HickmanPopulation Health Science, Bristol Medical School, University of Bristol, Bristol, UK.
University of Bristol · GBUniversity Hospitals Bristol NHS Foundation Trust · GBMRC Epidemiology Unit · GB

Funding

Medical Research Council G9815508Medical Research Council MC_PC_15018Medical Research Council MC_PC_19009Medical Research Council MC_UU_00011/6Medical Research Council MR/L022206/1Medical Research Council MR/M020894/1
6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) is the commonest liver condition in the western world and is directly linked to obesity and the metabolic syndrome. Elevated body mass index is regarded as a major risk factor of NAFL (steatosis) and NAFLD fibrosis. Using data from the Avon Longitudinal Study of Parents and Children (ALSPAC), we sought to investigate whether other variables from adolescence could improve prediction of future NAFL and NAFLD fibrosis risk at 24 years, above BMI and sex.

methodsAged 24 years, 4018 ALSPAC participants had transient elastography (TE) and controlled attenuation parameter (CAP) measurement using Echosens 502 Touch. 513 participants with harmful alcohol consumption were excluded. Logistic regression models examined which variables measured at 17 years were predictive of NAFL and NAFLD fibrosis in young adults. Predictors included sex, BMI, central adiposity, lipid profile, blood pressure, liver function tests, homeostatic model assessment for insulin resistance (HOMA-IR), and ultrasound defined NAFL at 17 years (when examining fibrosis outcomes). A model including all these variables was termed "routine clinical measures". Models were compared using area under the receiver operator curve (AUROC) and Bayesian Information Criterion (BIC), analysis, which penalises model complexity. Models were tested in all participants and those with overweight or obese standardised BMIs (BMI SDS) centiles at the 17-year time point. A decision curve analysis (DCA) was performed to evaluate the clinical utility of models in overweight and obese adolescents predicting NAFLD fibrosis at a threshold probability of 0.1.

resultsThe "routine clinical measures" model had the highest AUROC for predicting NAFL in all adolescent participants (AUROC 0.79 [SD 0.00]) and those with an overweight/obese BMI SDS centile (AUROC 0.77 [SD 0.01]). According to BIC analysis, insulin resistance was the best predictor of NAFL in all adolescents, whilst central adiposity was the best predictor in those with an overweight/obese BMI SDS centile. The "routine clinical measures" model also had the highest AUROC for predicting NAFLD fibrosis in all adolescent participants (AUROC 0.78 [SD 0.02]) and participants with an overweight/obese BMI SDS centile (AUROC 0.84 [SD 0.03]). However, following BIC analysis, BMI was the best predictor of NAFLD fibrosis in all adolescents including those with an overweight/obese BMI SDS centile. A decision curve analysis examining overweight/obese adolescent participants showed the model that had the greatest net benefit for increased NAFLD fibrosis detection, above a treat all overweight and obese adolescents' assumption, was the "routine clinical measures" model. However, the net benefit was marginal (0.0054 [0.0034-0.0075]).

conclusionIn adolescents, routine clinical measures were not superior to central adiposity and BMI at predicting NAFL and NAFLD fibrosis respectively in young adulthood. Additional routine clinical measurements do provide incremental benefit in detecting true positive fibrosis cases, but the benefit is small. Thus, to reduce morbidity and mortality associated with NASH cirrhosis in adults, the ultimate end point of NAFLD, the focus must be on obesity management at a population level.

Indexed as

Insulin ResistanceNon-alcoholic Fatty Liver DiseasePediatric ObesityAdolescentAdultBayes TheoremBody Mass IndexChildHumansLiver CirrhosisLongitudinal StudiesObesity, AbdominalOverweightYoung AdultALSPAC (Avon Longitudinal Study of Parents and Children)Body compositionNAFLD (nonalcoholc fatty liver disease)ObesityYoung adults

Identifiers

PMID35773644
PMCPMC9245230
OpenAlexW4283759733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.